Browsing Tag
Solid tumors
31 posts
French biotech company Step Pharma raises €35m in a Series B round
Step Pharma has raised €35 million in a Series B financing round for advancing STP938, its lead CTPS1…
Boehringer Ingelheim to acquire NBE-Therapeutics for €1.1bn
Boehringer Ingelheim has entered into a transformative €1.18 billion agreement to acquire NBE-Therapeutics, a clinical-stage biotech company based…
Merck’s $2.75bn acquisition of VelosBio: Strengthening its oncology pipeline
In a strategic move to bolster its oncology portfolio, U.S. pharmaceutical giant Merck & Co. has announced the…
VelosBio initiates Phase 2 trial for ROR1-targeting antibody-drug conjugate VLS-101 in solid tumors
VelosBio, a San Diego-based biopharmaceutical company, has reached a significant milestone in the development of its investigational antibody-drug…
Seattle Genetics signs $4.4bn worth oncology deals with Merck
US biotech company Seattle Genetics has secured deals worth up to $4.4 billion with Merck, that include two…
Blueprint Medicines strikes $1.7bn worth deal with Roche for pralsetinib
Swiss pharma giant Roche and US precision therapy company Blueprint Medicines have entered into a worldwide licensing and…
Unum Therapeutics acquires kinase inhibitors developer Kiq
Unum Therapeutics, a US biopharma company, has acquired Kiq, a biotech company focused on the discovery and development…
TScan, Novartis to develop T cell receptor therapies for solid tumors
TScan Therapeutics has partnered with Swiss pharma giant Novartis to discover and develop novel TCR-engineered T cell receptor…
Merck acquires ArQule for $2.7bn to further diversify oncology pipeline
Merck acquisition of ArQule : Merck has completed its previously announced acquisition of ArQule for $20 per share…
PACT Pharma raises $75m to develop neoTCR-T cell therapies for solid tumors
PACT Pharma, a California-based clinical stage company, which is focused on developing fully personalized neoTCR-T cell therapies for…